News | October 31, 2025
NATCO launches Everolimus tablets, 1 mg
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Expanding US operations to address the increased demand for API development and manufacturing
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Subscribe To Our Newsletter & Stay Updated
